Cargando…

Biochemical, biological and structural properties of romidepsin (FK228) and its analogs as novel HDAC/PI3K dual inhibitors

Romidepsin (FK228, depsipeptide) is a potent histone deacetylase (HDAC) inhibitor that has FDA approval for the treatment of cutaneous and peripheral T-cell lymphomas. We have previously reported that FK228 and its analogs have an additional activity as phosphatidylinositol 3-kinase (PI3K) inhibitor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Saijo, Ken, Imamura, Jin, Narita, Koichi, Oda, Akifumi, Shimodaira, Hideki, Katoh, Tadashi, Ishioka, Chikashi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BlackWell Publishing Ltd 2015
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4399029/ https://www.ncbi.nlm.nih.gov/pubmed/25492515 http://dx.doi.org/10.1111/cas.12585

Ejemplares similares

LPIN1 downregulation enhances anticancer activity of the novel HDAC/PI3K dual inhibitor FK‐A11
por: Imai, Hiroo, et al.
Publicado: (2021)

Antitumor activity and pharmacologic characterization of the depsipeptide analog as a novel histone deacetylase/ phosphatidylinositol 3‐kinase dual inhibitor
por: Saijo, Ken, et al.
Publicado: (2017)

Romidepsin (FK228) regulates the expression of the immune checkpoint ligand PD-L1 and suppresses cellular immune functions in colon cancer
por: Shi, Yehui, et al.
Publicado: (2020)

Romidepsin (FK228) in a Mouse Model of Lipopolysaccharide-Induced Acute Kidney Injury is Associated with Down-Regulation of the CYP2E1 Gene
por: Cheng, Shulin, et al.
Publicado: (2020)

FK228 from Burkholderia thailandensis MSMB43
por: Liu, Xiang-Yang, et al.
Publicado: (2012)

In Vitro and in Vivo antitumor activity and the mechanism of siphonodictyal B in human colon cancer cells
por: Chikamatsu, Sonoko, et al.
Publicado: (2019)

The HDAC Inhibitor FK228 Enhances Adenoviral Transgene Expression by a Transduction-Independent Mechanism but Does Not Increase Adenovirus Replication
por: Danielsson, Angelika, et al.
Publicado: (2011)

FK228 Analogues Induce Fetal Hemoglobin in Human Erythroid Progenitors
por: Makala, Levi, et al.
Publicado: (2012)

The structural basis of an NADP(+)-independent dithiol oxidase in FK228 biosynthesis
por: Li, Jie, et al.
Publicado: (2014)

FK228 sensitizes radioresistant small cell lung cancer cells to radiation
por: Li, Hong, et al.
Publicado: (2021)

Mechanistic studies of DepR in regulating FK228 biosynthesis in Chromobacterium violaceum no. 968
por: Qiao, Yongjian, et al.
Publicado: (2018)

Apoptotic Cytotoxic Effects of a Histone Deacetylase Inhibitor, FK228, on Malignant Lymphoid Cells
por: Murata, Makoto, et al.
Publicado: (2000)

Genomics-guided discovery of a new and significantly better source of anticancer natural drug FK228
por: Liu, Xiangyang, et al.
Publicado: (2018)

HDAC1/2 Inhibitor Romidepsin Suppresses DEN-Induced Hepatocellular Carcinogenesis in Mice
por: Afaloniati, Hara, et al.
Publicado: (2020)

HDAC Screening Identifies the HDAC Class I Inhibitor Romidepsin as a Promising Epigenetic Drug for Biliary Tract Cancer
por: Mayr, Christian, et al.
Publicado: (2021)

R-Loop–Mediated ssDNA Breaks Accumulate Following Short-Term Exposure to the HDAC Inhibitor Romidepsin
por: Safari, Maryam, et al.
Publicado: (2021)

Treating Colon Cancer Cells with FK228 Reveals a Link between Histone Lysine Acetylation and Extensive Changes in the Cellular Proteome
por: Wang, Tian-yun, et al.
Publicado: (2015)

In vivo Effects of a Histone Deacetylase Inhibitor, FK228, on Human Acute Promyelocytic Leukemia in NOD/Shi‐scid/scid Mice
por: Kosugi, Hiroshi, et al.
Publicado: (2001)

Combinatorial Antitumor Activity of Oxaliplatin with Epigenetic Modifying Agents, 5-Aza-CdR and FK228, in Human Gastric Cancer Cells
por: Park, Jong Kook, et al.
Publicado: (2018)

Romidepsin-induced neutrophilic urticaria
por: Scott, Brian, et al.
Publicado: (2016)

High throughput RNAi screening identifies ID1 as a synthetic sick/lethal gene interacting with the common TP53 mutation R175H
por: IMAI, HIROO, et al.
Publicado: (2014)

Structure-Guided Synthesis of FK506 and FK520 Analogs with Increased Selectivity Exhibit In Vivo Therapeutic Efficacy against Cryptococcus
por: Hoy, Michael J., et al.
Publicado: (2022)

Romidepsin in the treatment of cutaneous T-cell lymphoma
por: Jain, Salvia, et al.
Publicado: (2011)

Romidepsin for the Treatment of Peripheral T-Cell Lymphoma
por: Barbarotta, Lisa, et al.
Publicado: (2015)

Upper Arm Central Venous Port Implantation: A 6-Year Single Institutional Retrospective Analysis and Pictorial Essay of Procedures for Insertion
por: Shiono, Masatoshi, et al.
Publicado: (2014)

Functional Complementation Assay for 47 MUTYH Variants in a MutY-Disrupted Escherichia Coli Strain
por: Komine, Keigo, et al.
Publicado: (2015)

HDAC inhibitors Panobinostat and Romidepsin enhance tax transcription in HTLV-1-infected cell lines and freshly isolated patients’ T-cells
por: Schnell, Annika P., et al.
Publicado: (2022)

The decay scheme of $^{228}$Fr and $K=0$ bands in $^{228}$Ra
por: Ruchowska, E, et al.
Publicado: (1982)

Pharmacokinetics and Immunological Effects of Romidepsin in Rhesus Macaques
por: Kleinman, Adam J., et al.
Publicado: (2020)

Efficacy and safety of gemcitabine plus docetaxel in Japanese patients with unresectable or recurrent bone and soft tissue sarcoma: Results from a single-institutional analysis
por: Takahashi, Masanobu, et al.
Publicado: (2017)

Inhibition of IRAK1/4 enhances the antitumor effect of lenvatinib in anaplastic thyroid cancer cells
por: Kawamura, Yoshifumi, et al.
Publicado: (2021)

Deciphering the molecular effects of romidepsin on germ cell tumours: DHRS2 is involved in cell cycle arrest but not apoptosis or induction of romidepsin effectors
por: Nettersheim, Daniel, et al.
Publicado: (2018)

Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma
por: Foss, Francine, et al.
Publicado: (2014)

The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo
por: Søgaard, Ole S., et al.
Publicado: (2015)

Romidepsin targets multiple survival signaling pathways in malignant T cells
por: Valdez, B C, et al.
Publicado: (2015)

Long-Term Treatment with Romidepsin in Patients with Peripheral T-Cell Lymphoma
por: Irlé, Claudius, et al.
Publicado: (2016)

Synergistic Effect of Simvastatin and Romidepsin on Gamma-globin Gene Induction
por: Habibi, Hussain, et al.
Publicado: (2019)

Immunosuppression-associated primary cutaneous plasmablastic lymphoma secondary to romidepsin
por: Costello, Collin M., et al.
Publicado: (2019)

Simvastatin-romidepsin combination kills bladder cancer cells synergistically
por: Okubo, Kazuki, et al.
Publicado: (2021)

microRNA-193a-3p is specifically down-regulated and acts as a tumor suppressor in BRAF-mutated colorectal cancer
por: Takahashi, Hidekazu, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_9nt5mnm6duedqvp4kejlnmshrg